UroGen Pharma (URGN) Stock Overview
Engages in the development and commercialization of solutions for urothelial and specialty cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
URGN Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
UroGen Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.40 |
| 52 Week High | US$19.74 |
| 52 Week Low | US$3.42 |
| Beta | 1.03 |
| 1 Month Change | 42.86% |
| 3 Month Change | 77.17% |
| 1 Year Change | 23.72% |
| 3 Year Change | 126.37% |
| 5 Year Change | -16.23% |
| Change since IPO | 38.77% |
Recent News & Updates
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
Jul 07
Recent updates
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
Jul 07UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation
Jun 10Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
May 17Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
May 15
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
Feb 12UroGen: Upcoming PDUFA, Some Concerns Remain
Jan 31Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
Nov 18UroGen Pharma: There Is Some Potential Here
Aug 28UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Jun 17UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jun 14UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18Shareholder Returns
| URGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | -1.9% | -2.7% |
| 1Y | 23.7% | -8.4% | 17.7% |
Return vs Industry: URGN exceeded the US Biotechs industry which returned -12.5% over the past year.
Return vs Market: URGN exceeded the US Market which returned 16.8% over the past year.
Price Volatility
| URGN volatility | |
|---|---|
| URGN Average Weekly Movement | 27.2% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: URGN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: URGN's weekly volatility has increased from 15% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 234 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
UroGen Pharma Ltd. Fundamentals Summary
| URGN fundamental statistics | |
|---|---|
| Market cap | US$896.31m |
| Earnings (TTM) | -US$138.43m |
| Revenue (TTM) | US$91.87m |
Is URGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| URGN income statement (TTM) | |
|---|---|
| Revenue | US$91.87m |
| Cost of Revenue | US$9.48m |
| Gross Profit | US$82.39m |
| Other Expenses | US$220.82m |
| Earnings | -US$138.43m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 07, 2025
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 89.68% |
| Net Profit Margin | -150.68% |
| Debt/Equity Ratio | -262.8% |
How did URGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/03 01:13 |
| End of Day Share Price | 2025/08/01 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
UroGen Pharma Ltd. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Jonathan Aschoff | B. Riley Wealth |
| Jason Kolbert | D. Boral Capital LLC. |